TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
Company Details
- Founded
- -
- Address
- 265 Strand, London,wc2r 1bh,united Kingdom
- in****@****ert.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.topivert.com/
- HQ
- London
Topivert Pharma Limited Questions
Topivert Pharma Limited's website is http://www.topivert.com/
Topivert Pharma Limited's LinkedIn profile is https://uk.linkedin.com/company/topivert-pharma-limited
Topivert Pharma Limited's industry is
Pharmaceutical Manufacturing
Topivert Pharma Limited's top competitors are
Kesmalea Therapeutics,
Mestag Therapeutics,
Mati Therapeutics, Inc.,
Wellstat Therapeutics Corporation,
Molecular Vision,
Wellstat Group Of Companies,
Pharma Optima,
Masthead Biosciences,
Cognoptix,
Hubble.
Topivert Pharma Limited's support email address is info@topivert.com
Topivert Pharma Limited's categories are Pharmaceutical Manufacturing
Topivert Pharma Limited's founding year is 2011
